These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 9737924

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2.
    Piehler J, Schreiber G.
    J Mol Biol; 1999 Nov 19; 294(1):223-37. PubMed ID: 10556041
    [Abstract] [Full Text] [Related]

  • 4. Functional cartography of the ectodomain of the type I interferon receptor subunit ifnar1.
    Lamken P, Gavutis M, Peters I, Van der Heyden J, Uzé G, Piehler J.
    J Mol Biol; 2005 Jul 15; 350(3):476-88. PubMed ID: 15946680
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Variations in the unstructured C-terminal tail of interferons contribute to differential receptor binding and biological activity.
    Slutzki M, Jaitin DA, Yehezkel TB, Schreiber G.
    J Mol Biol; 2006 Jul 28; 360(5):1019-30. PubMed ID: 16815442
    [Abstract] [Full Text] [Related]

  • 7. Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers.
    Lamken P, Lata S, Gavutis M, Piehler J.
    J Mol Biol; 2004 Jul 30; 341(1):303-18. PubMed ID: 15312780
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2.
    Marijanovic Z, Ragimbeau J, van der Heyden J, Uzé G, Pellegrini S.
    Biochem J; 2007 Oct 01; 407(1):141-51. PubMed ID: 17627610
    [Abstract] [Full Text] [Related]

  • 10. NMR backbone dynamics of the human type I interferon binding subunit, a representative cytokine receptor.
    Chill JH, Quadt SR, Anglister J.
    Biochemistry; 2004 Aug 10; 43(31):10127-37. PubMed ID: 15287740
    [Abstract] [Full Text] [Related]

  • 11. Functional significance of globotriaosyl ceramide in interferon-alpha(2)/type 1 interferon receptor-mediated antiviral activity.
    Khine AA, Lingwood CA.
    J Cell Physiol; 2000 Jan 10; 182(1):97-108. PubMed ID: 10567921
    [Abstract] [Full Text] [Related]

  • 12. Stat2 binding to the interferon-alpha receptor 2 subunit is not required for interferon-alpha signaling.
    Nguyen VP, Saleh AZ, Arch AE, Yan H, Piazza F, Kim J, Krolewski JJ.
    J Biol Chem; 2002 Mar 22; 277(12):9713-21. PubMed ID: 11786546
    [Abstract] [Full Text] [Related]

  • 13. Homology model of human interferon-alpha 8 and its receptor complex.
    Seto MH, Harkins RN, Adler M, Whitlow M, Church WB, Croze E.
    Protein Sci; 1995 Apr 22; 4(4):655-70. PubMed ID: 7613464
    [Abstract] [Full Text] [Related]

  • 14. Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation.
    Russell-Harde D, Wagner TC, Perez HD, Croze E.
    Biochem Biophys Res Commun; 1999 Feb 16; 255(2):539-44. PubMed ID: 10049744
    [Abstract] [Full Text] [Related]

  • 15. A role for Janus kinases in crosstalk between ErbB3 and the interferon-alpha signaling complex in myeloma cells.
    Walters DK, Jelinek DF.
    Oncogene; 2004 Feb 12; 23(6):1197-205. PubMed ID: 14647450
    [Abstract] [Full Text] [Related]

  • 16. Structure-function study of the extracellular domain of the human IFN-alpha receptor (hIFNAR1) using blocking monoclonal antibodies: the role of domains 1 and 2.
    Lu J, Chuntharapai A, Beck J, Bass S, Ow A, De Vos AM, Gibbs V, Kim KJ.
    J Immunol; 1998 Feb 15; 160(4):1782-8. PubMed ID: 9469437
    [Abstract] [Full Text] [Related]

  • 17. Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity.
    Runkel L, deDios C, Karpusas M, Betzenhauser M, Muldowney C, Zafari M, Benjamin CD, Miller S, Hochman PS, Whitty A.
    Biochemistry; 2000 Mar 14; 39(10):2538-51. PubMed ID: 10704203
    [Abstract] [Full Text] [Related]

  • 18. Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34-positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia.
    Ito K, Tanaka H, Ito T, Sultana TA, Kyo T, Imanaka F, Ohmoto Y, Kimura A.
    Eur J Haematol; 2004 Sep 14; 73(3):191-205. PubMed ID: 15287917
    [Abstract] [Full Text] [Related]

  • 19. The IFNAR1 subunit of the type I IFN receptor complex contains a functional nuclear localization sequence.
    Subramaniam PS, Johnson HM.
    FEBS Lett; 2004 Dec 17; 578(3):207-10. PubMed ID: 15589821
    [Abstract] [Full Text] [Related]

  • 20. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta.
    Jaitin DA, Roisman LC, Jaks E, Gavutis M, Piehler J, Van der Heyden J, Uze G, Schreiber G.
    Mol Cell Biol; 2006 Mar 17; 26(5):1888-97. PubMed ID: 16479007
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.